WO2011090345A3 - Novel antibiotic composition comprising flufenamic acid as an active ingredient - Google Patents

Novel antibiotic composition comprising flufenamic acid as an active ingredient Download PDF

Info

Publication number
WO2011090345A3
WO2011090345A3 PCT/KR2011/000444 KR2011000444W WO2011090345A3 WO 2011090345 A3 WO2011090345 A3 WO 2011090345A3 KR 2011000444 W KR2011000444 W KR 2011000444W WO 2011090345 A3 WO2011090345 A3 WO 2011090345A3
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
flufenamic acid
antibiotic
antibiotic composition
novel antibiotic
Prior art date
Application number
PCT/KR2011/000444
Other languages
French (fr)
Korean (ko)
Other versions
WO2011090345A2 (en
Inventor
김경규
강성욱
Original Assignee
성균관대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성균관대학교산학협력단 filed Critical 성균관대학교산학협력단
Priority to US13/522,764 priority Critical patent/US9238016B2/en
Publication of WO2011090345A2 publication Critical patent/WO2011090345A2/en
Publication of WO2011090345A3 publication Critical patent/WO2011090345A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a novel antibiotic, and more specifically relates to an antibiotic composition comprising flufenamic acid as an active ingredient, which can reduce drug toxicity and side effects and the problem of antibiotic resistance caused by excessive use of antibiotics since the composition exhibits a good therapeutic effect, even in a small dose, when it is administered either alone or together with another antibiotic of the prior art.
PCT/KR2011/000444 2010-01-22 2011-01-21 Novel antibiotic composition comprising flufenamic acid as an active ingredient WO2011090345A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/522,764 US9238016B2 (en) 2010-01-22 2011-01-21 Antibiotic composition comprising flufenamic acid as an active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100006217A KR101141938B1 (en) 2010-01-22 2010-01-22 Novel antibiotic compounds and methods for treating gram positive bacterial infections
KR10-2010-0006217 2010-01-22

Publications (2)

Publication Number Publication Date
WO2011090345A2 WO2011090345A2 (en) 2011-07-28
WO2011090345A3 true WO2011090345A3 (en) 2011-12-29

Family

ID=44307414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000444 WO2011090345A2 (en) 2010-01-22 2011-01-21 Novel antibiotic composition comprising flufenamic acid as an active ingredient

Country Status (3)

Country Link
US (1) US9238016B2 (en)
KR (1) KR101141938B1 (en)
WO (1) WO2011090345A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3115048C (en) * 2018-09-28 2024-02-13 Griffith University Agents and methods for modulating pathogen activity using ligands of complement receptor 3

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100759988B1 (en) * 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 Antimicrobial protein specific to staphylococcus aureus
KR20080008321A (en) * 2005-03-03 2008-01-23 아이에스더블유 그룹, 인크. Topical gels compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL45357A (en) * 1974-07-26 1978-04-30 Yeda Res & Dev Pharmaceutical compositions comprising aromatic amino acids as inhibitors of prostaglandin action
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080008321A (en) * 2005-03-03 2008-01-23 아이에스더블유 그룹, 인크. Topical gels compositions
KR100759988B1 (en) * 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 Antimicrobial protein specific to staphylococcus aureus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BETHAN ET AL.: "Recent human-to-poultry host jump, adaptation, and pandemic spread of Staphylococcus aureus", PNAS, vol. 106, no. 46, 17 November 2009 (2009-11-17), pages 19545 - 19550 *
DATABASE GENBANK 27 October 2009 (2009-10-27), "aldo/keto reductase family", retrieved from ACY10586 Database accession no. ACY10586 *
DATABASE GENBANK 27 October 2009 (2009-10-27), "aldo/keto reductase family[Staphylococcus aureus subsp. aureus ED98]", Database accession no. ACY11686 *
DATABASE GENBANK 27 October 2009 (2009-10-27), "aldo/keto reductase family[Staphylococcus aureus subsp. aureus ED98]", retrieved from ACY12095 Database accession no. ACY12095 *

Also Published As

Publication number Publication date
US9238016B2 (en) 2016-01-19
WO2011090345A2 (en) 2011-07-28
KR101141938B1 (en) 2012-05-04
KR20110086466A (en) 2011-07-28
US20130143856A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
MX348653B (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof.
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
EP4309735A3 (en) Pharmaceutical composition of s-ketamine hydrochloride
WO2015021382A3 (en) Topical compositions and methods of using the same
EP2583684A4 (en) Peptide having antimicrobial or anti-inflammatory activity and pharmaceutical composition containing same as an active ingredient
WO2012064973A3 (en) Heterocyclic compounds and uses thereof
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
WO2011012816A3 (en) Pharmaceutical formulation
WO2013106761A3 (en) Antimicrobial agents
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors
IL220894A (en) Active ingredient combinations comprising dihydrofuranone derivatives and abamectin, mixture/beneficial species combinations and kit comprising same and uses thereof
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2014101295A3 (en) Isoxazole derivative that inhibits activity of janus kinases (jaks)
MX340985B (en) N-heteroaryl compounds.
WO2011019326A3 (en) Solubility and stability enchancing pharmaceutical formulation
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2014060638A8 (en) A veterinary method of alleviating noise aversion
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
WO2011139256A3 (en) Stable rosuvastatin formulations
WO2011135580A3 (en) Pharmaceutical compositions of sirolimus
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
MX2014014579A (en) O/w-emulsion-type topical pharmaceutical compositions containing a retinoid.
EP2682129A3 (en) Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11734894

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13522764

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11734894

Country of ref document: EP

Kind code of ref document: A2